Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 829 of 6351
-
Spirulina extract put to the test against long COVID inflammation
Disease control CompletedThis is a multi-site study that will try to determine the effects of Immulina ™, a natural dietary supplement, on blood chemicals associated with inflammation that are often increased in patients with long COVID (also called PASC).
Phase 3 • Sponsor: University of Mississippi Medical Center • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New pill could ease stiffness and pain for ankylosing spondylitis patients
Disease control OngoingThis is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of Jaktinib in subjects with active Ankylosing Spondylitis(AS).
Phase 3 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Can a skin ointment calm two stubborn redness conditions?
Disease control Stopped earlyThis study is a double-blind, vehicle-controlled clinical trial. The study will take place at Icahn School of Medicine at Mount Sinai. The study will include 33-39 adult subjects with moderate-to-severe-Seborrheic dermatitis (SD) as well as 33-39 adult subjects with moderate-to-s…
Phase 2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Could a One-Month TB pill be as good as three? new trial tests shorter prevention
Prevention OngoingA multicenter, randomized, stratified, open-label, phase IV trial among HIV-positive persons (PLHIV) on antiretroviral therapy (ART), or HIV-negative household contacts of patients with rifampicin-sensitive pulmonary tuberculosis (TB), who do not have evidence of active TB.
Phase 4 • Sponsor: The Aurum Institute NPC • Aim: Prevention
Last updated Jun 27, 2026 08:03 UTC
-
Should mildly Brain-Injured newborns be cooled? major trial aims to find out
Disease control Recruiting nowTo determine effectiveness of therapy to improve neurodevelopmental outcomes in infants with mild HIE. To determine the adverse effects of Therapeutic Hypothermia (TH) in mild HIE on the neonate and his/her family. Determine heterogeneity of the treatment effect across key subgro…
Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug combo shows promise in lung cancer trial
Disease control OngoingA Phase II clinical study to evaluate the efficacy and safety of BL-B01D1 for injection and BL-B01D1 in combination with Osimertinib Mesylate Tablets in patients with locally advanced or metastatic non-small cell lung cancer.
Phase 2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 18:49 UTC
-
New drug cocktail shows promise for Hard-to-Treat lung cancer
Disease control OngoingThis study will assess the safety and efficacy of Osimertinib with Amivantamab as First-line Treatment in Participants with Epidermal Growth Factor Receptor Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC).
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Nature as therapy? a new trial tests outdoor outings for anxious kids
Symptom relief CancelledIn 2019, the Office of the California Surgeon General launched the ACEs Aware Initiative in collaboration with the California Department of Health Care Services. This ambitious campaign aims to develop a network of care model of healthcare delivery that explicitly links health re…
Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Which Tear-Duct surgery works better? a Head-to-Head test
Disease control CompletedPrimary acquired nasolacrimal duct obstruction causes persistent tearing because tears cannot drain normally from the eye into the nose. The purpose of this randomized study was to compare two operations used to restore tear drainage: external dacryocystorhinostomy, performed thr…
Sponsor: Military Institute od Medicine National Research Institute • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Head-to-head trial aims to find best way to save sight in IIH patients
Disease control Recruiting nowBackground and study aims Idiopathic intracranial hypertension (IIH) is a neurological condition characterised by increased pressure inside the skull, called intracranial pressure (ICP). It is more common in women of reproductive age with obesity. Common symptoms of IIH include h…
Sponsor: University of Birmingham • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New hope for advanced breast cancer: A166 takes on T-DM1 in head-to-head trial
Disease control OngoingEvaluation of the efficacy of A166 versus trastuzumab emtansine (T-DM1) in Patients with HER2-Positive unresectable or metastatic breast cancer previously treated with trastuzumab and taxane therapy
Phase 3 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug combo takes on aggressive breast cancer
Disease control OngoingThe purpose of this study is to assess the efficacy and safety of a novel immunotherapy candidate, tobemstomig, in combination with nab-paclitaxel, for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-po…
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New drug cocktail aims to tackle tough leukemia
Disease control Recruiting nowZiftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This protocol has 3 separate arms that will investigate the benefits and risks of adding ziftomenib to standard-of-care (SOC) dr…
Phase 1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug combo aims to tackle lymphoma without chemo
Disease control OngoingThe purpose of this study is to determine how effective and safe the combination of glofitamab and obinutuzumab is in treating patients with Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) who have not received other treatments for their lymphoma. The names of the stud…
Phase 2 • Sponsor: Reid Merryman, MD • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Ancient herbal formula put to the test against Age-Related muscle loss
Disease control OngoingSarcopenia is an age-related condition characterized by progressive loss of muscle mass, muscle strength, and physical function. It may also be associated with impaired cognitive function. Effective treatment options for sarcopenia remain limited. This multicenter, randomized, d…
Sponsor: Fujian University of Traditional Chinese Medicine • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Triple therapy shows promise in shrinking sarcomas before surgery
Disease control OngoingThis is a phase II single-arm single-stage study evaluating efficacy and safety of pembrolizumab in combination with a soluble LAG-3 protein, eftilagimod alfa (Efti) and radiotherapy in neoadjuvant treatment of patients with soft tissue sarcomas. This study will determine the pat…
Phase 2 • Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New hope for rare cancer: drug combo targets Tough-to-Treat neuroendocrine tumors
Disease control Recruiting nowThis is the first study to be done in a newly described class of neuroendocrine tumors known as well-differentiated grade 3 neuroendocrine tumors (WD G3 NET). First described in the pancreas in 2017, the classification was broadened to include gastrointestinal tract tumors in 201…
Phase 2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Can a weekly shot help obese teens avoid diabetes and fatty liver?
Disease control OngoingThe purpose of this study is to understand the role of GLP-1 in the pathogenesis of T2D in youth and explore their potential salutary effects and ability to delay the progressive loss of ß-cell function and reduce hepatic steatosis in youth with prediabetes/new onset T2D and NAFL…
Phase 2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New Clot-Busting catheter procedure could ease recovery for lung blood clot patients
Disease control Recruiting nowPE-TRACT is an open-label, assessor-blinded, randomized trial, aiming to compare catheter-directed therapy (CDT) and anticoagulation (CDT group) with anticoagulation alone (No-CDT) in 500 patients with submassive PE, proximal pulmonary artery thrombus and right ventricular dilati…
Phase 3 • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Can a heart drug mend damage from breast cancer therapy?
Disease control OngoingThe purpose of this study is to find out if adding vericiguat to standard treatment for cancer therapy related cardiac dysfunction (CTRCD) is more effective than standard treatment alone. The addition of vericiguat to the usual treatment could help improve cardiac function, but i…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC